7 questions on Biogen's revival of a failed Alzheimer's drug

Biogen stunned investors and Alzheimer's researchers on Tuesday with news it will ask the Food and Drug Administration to approve its experimental drug aducanumab.

Just seven months ago, Biogen shut down two large Phase 3 studies after a first look at the data signaled the trials were unlikely to prove positive.